PATENT CLAIM ANALYSIS

Application Number: 15754414
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-08
Patent Classification: ["514", "416000"]

Abstract:
The present invention relates to pharmaceutical compositions comprising the active substance Lenalidomide in one of the modifications selected from Lenalidomide base, a Lenalidomide salt, a Lenalidomide cocrystal or mixtures thereof, wherein the Lenalidomide particles have a particle size distribution (d 90 ) ranging from 1 μm to 100 μm.

Claim (Index 23):
The oral solid pharmaceutical composition according to  claim 14 , wherein the one or more filler(s) are selected from microcrystalline cellulose (MCC), silicified microcrystalline cellulose (SMCC), lactose monohydrate, lactose anhydrous, mannitol, sucrose, di calcium phosphate, calcium carbonate, magnesium carbonate, pregelatinized starch, low substituted hydroxypropyl cellulose (L-HPC), powder cellulose, calcium silicate, calcium phosphate, sorbitol, mannitol, dextrines, kaolin, magnesium oxide, calcium sulfate, xylitol, isomalt, glucose, fructose, maltose, acids including citric acid, tartaric acid, fumaric acid and co-polymers from vinyl pyrrolidone and vinyl acetate or co-polymers of polyethylene glycol.

Metadata:
- Claim Count in Document: 8.0
- Percentile: 88.0
- Lexical Diversity: 1.31707
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['14780495', '15852125', '11776012', '15387317', '13736699']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7362324908770447
- 35 USC 102 Novelty (BERT): 0.4979741588123614
- Combined Prediction Score: 0.7124066576705763
- Mean Citation Score: 200.706194
- Max Citation Score: 204.72156
- Similarity Product: 144.7346443581462

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test